Pizu Group Holdings Limited

比優集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9893)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board announces that with effect from 10 July 2026:

(1) Mr. Hu Jingqiang has resigned as an independent non-executive director and a member of each of the audit committee, the remuneration committee and the nomination committee of the Board; and

(2) Dr. Wei Lai has been appointed as an independent non-executive director and a member of each of the audit committee, the remuneration committee and the nomination committee of the Board.

The board (the "**Board**") of directors (the "**Directors**" and each, a "**Director**") of Pizu Group Holdings Limited (the "**Company**") is pleased to announce that:

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Hu Jingqiang ("**Mr. Hu**") has resigned as an independent non-executive Director and a member of each of the audit committee, the remuneration committee and the nomination committee of the Board with effect from 10 July 2026 in order to devote more time to his other business engagements.

Mr. Hu has confirmed that (i) he has no claim against the Company, its subsidiaries or affiliates; and (ii) he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its gratitude to Mr. Hu for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Dr. Wei Lai ("**Dr. Wei**") has been appointed as an independent non-executive Director and a member of each of the audit committee, the remuneration committee and the nomination committee of the Board with effect from 10 July 2026.

Dr. Wei, aged 37, has served as a professor and head of the department of finance of Lingnan University (嶺南大學), since September 2023 and since May 2024, respectively. Prior to that, Dr. Wei served as an associate professor and an assistant professor of Lingnan University (嶺南大學) from September 2019 to August 2023 and from September 2016 to August 2019, respectively. Dr. Wei obtained a bachelor's degree of economics and finance from the University of Hong Kong (香港大學) in August 2012 and a doctor's degree in finance from the University of Hong Kong (香港大學) in August 2016. Dr. Wei has also served as an independent director of Sungrow Power Supply Co., Ltd. (陽光電源股份有限公司), a company listed on the ChiNext Market of the Shenzhen Stock Exchange (stock code: 300274), since 24 April 2026.

The appointment of Dr. Wei as an independent non-executive Director is subject to the articles of association of the Company (the "**Articles**"). Pursuant to Article 83(3) of the Articles, Dr. Wei shall hold office until the next annual general meeting of the Company and shall then be eligible for re-election. The Company has entered into an appointment letter with Dr. Wei for a term of three years commencing on 10 July 2026. Under the appointment letter, Dr. Wei is entitled to an annual Director's fee of HK$120,000 for her appointment as an independent non-executive Director and a member of each of the audit committee, the remuneration committee and the nomination committee of the Board. Such remuneration has been determined by reference to her roles and responsibilities and prevailing market conditions. Save for the above Director's fee, Dr. Wei is not entitled to any other emoluments for holding the above offices.

Dr. Wei has confirmed that (i) she satisfies the independence criteria as set out in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"); (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, Dr. Wei has confirmed that (i) she does not hold any other position in the Company or any of its subsidiaries, and has not held any directorship in any other listed public company in the last three years; (ii) she does not have any relationship with any Directors, senior management, substantial shareholder or controlling shareholder of the Company; and (iii) she does not have, and is not deemed to have, any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

As at the date of this announcement, save as disclosed herein, there are no other matters in relation to the appointment of Dr. Wei that need to be brought to the attention of the Shareholders, and no other information is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Dr. Wei to join the Board as an independent non-executive Director and a member of each of the audit committee, the remuneration committee and the nomination committee of the Company.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that Dr. Wei has been appointed as a member of the audit committee, the remuneration committee and the nomination committee, in place of Mr. Hu, with effect from 10 July 2026.

By order of the Board
Pizu Group Holdings Limited
Ma Tianyi
Chairman and Chief Executive Officer

Hong Kong, 10 July 2026

As at the date of this announcement, the Board comprises eight Directors. The executive Directors are Mr. Ma Tianyi (Chairman and Chief Executive Officer), Mr. Liu Fali (Chief Operating Officer), Ms. Qin Chunhong, Ms. Ma Ye and Mr. Ma Yong; and the independent non-executive Directors are Dr. Li Xu, Mr. Ha Suoku and Dr. Wei Lai.